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Abstract
Objectives—To estimate the predictive value of self-reported hepatitis A vaccine (HepA) receipt 
for the presence of hepatitis A virus (HAV) antibody (anti-HAV) from either past infection or 
vaccination, as an indicator of HAV protection.
Methods—Using 2007–2012 National Health and Nutrition Examination Survey data, we 
assigned participants to 4 groups based on self-reported HepA receipt and anti-HAV results. We 
compared characteristics across groups and calculated three measures of agreement between self-
report and serologic status (anti- HAV): percentage concordance, and positive (PPV) and negative 
(NPV) predictive values. Using logistic regression we investigated factors associated with 
agreement between self-reported vaccination status and serological results.
Results—Demographic and other characteristics varied significantly across the 4 groups. Overall 
agreement between self-reported HepA receipt and serological results was 63.6% (95% confidence 
interval [CI] 61.9–65.2); PPV and NPV of self-reported vaccination status for serological result 
were 47.0% (95% CI 44.2–49.8) and 69.4% (95% CI 67.0–71.8), respectively. Mexican American 
and foreign-born adults had the highest PPVs (71.5% [95% CI 65.9–76.5], and 75.8% [95% CI 
71.4–79.7]) and the lowest NPVs (21.8% [95% CI 18.5–25.4], and 20.0% [95% CI 17.2–23.1]), 
respectively. Young (ages 20–29 years), US-born, and non-Hispanic White adults had the lowest 
*Corresponding author at: Centers for Disease Control and Prevention, 1600 Clifton Road, NE, MailStop G-37, Atlanta, GA 30329, 
United States. Tel.: +1 404 718 8560; fax: +1 404 718 8588. 
Disclaimer
The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the Centers for 
Disease Control and Prevention.
Contributors
MMD contributed to conception of the study, design of the analytic plan, analysis and interpretation of the data, and writing and 
reviewing the manuscript. RMK and RBJ contributed to design of the analytic plan, interpretation of results, and writing and 
reviewing the manuscript. TVM generated the research questions, and contributed to design of the analytic plan, interpretation of 





Vaccine. Author manuscript; available in PMC 2016 July 31.
Published in final edited form as:













PPVs (37.9% [95% CI 34.5–41.5], 39.1% [95% CI, 36.0–42.3], and 39.8% [36.1–43.7]), and the 
highest NPVs (76.9% [95% CI 72.2–81.0, 78.5% [95% CI 76.5–80.4)], and 80.6% [95% CI 78.2–
82.8), respectively. Multivariate logistic analyses found age, race/ethnicity, education, place of 
birth and income to be significantly associated with agreement between self-reported vaccination 
status and serological results.
Conclusions—When assessing hepatitis A protection, self-report of not having received HepA 
was most likely to identify persons at risk for hepatitis A infection (no anti-HAV) among young, 
US-born and non-Hispanic White adults, and self-report of HepA receipt was least likely to be 
reliable among adults with the same characteristics.
Keywords
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1. Introduction
In the 1980s and 1990s, large areas of the United States experienced cyclic outbreaks of 
hepatitis A virus (HAV) disease [1]. To reduce the burden of HAV disease, from 1996 to 
2007 the Advisory Committee on Immunization Practices (ACIP) made recommendations 
for use of hepatitis A vaccines (HepA), which were first approved in 1995–1996 [2–5]. 
Initial recommendations were for adults at increased risk for HAV infection, including 
persons planning international travel to HAV endemic areas (1996) and for children aged ≥2 
years residing in areas where incidence was at least twice the U.S. average (1999). 
Subsequent HepA recommendations added all children starting at age 12–23 months (2006), 
persons wishing HAV protection, and post-exposure prophylaxis for healthy persons aged 1 
to <40 years [2–5].
As vaccination coverage increased in the United States, rates of acute HAV disease 
declined. In 2011, rates had decreased by more than 95% and were the lowest recorded [6]. 
Declines were greatest among children recommended to receive routine hepatitis A 
vaccination. In 2012, although rates continued to decline among children aged 0–9 years, the 
rates and proportion of hepatitis A cases among adults increased [7]. Complications and 
severe HAV disease are most likely to occur among adults [8].
Early evidence suggests a growing proportion of the adult population has no evidence of 
hepatitis A protection, which usually would have been acquired at a young age when HAV 
was endemic in the United States [9]. Providers and public health personnel evaluating 
adults for hepatitis A vaccination must rely on self-reported HepA receipt or disease history 
when records are not available [10]. In 2013, a domestic outbreak of HAV infection 
associated with imported HAV-contaminated pomegranate arils resulted in 165 cases in 10 
states. Ninety-three percent of cases were among adults aged ≥18 years, and 45% of adults 
were hospitalized. One retailer alone evaluated more than 10,000 people for post-exposure 
prophylaxis with HepA [11].
The predictive value of self-reported vaccination history for HAV protection among adults 
has received limited evaluation [10,12]. Antibody to HAV (anti-HAV) results from either 
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vaccination or infection and is considered a marker of protection from HAV infection 
[13,14]. The National Health and Nutrition Examination Survey (NHANES) provides a 
unique opportunity to examine the correlation between self-reported HepA receipt and 
serological test results in the general U.S. population. We used 2007–2012 NHANES data 
from participants aged ≥20 years to calculate measures of agreement and identify factors 
associated with agreement between self-report and protection against HAV infection.
2. Methods and materials
2.1. Survey design
The NHANES, conducted by the U.S. Centers for Disease Control and Prevention’s (CDC) 
National Center for Health Statistics (NCHS), collects nationally representative data on 
health and nutritional status from the non-institutionalized civilian U.S. population. 
NHANES uses a complex probability sampling design and collects information from 
approximately 5000 persons per year using standardized household interviews, physical 
examinations, and tests of biologic samples. Participants are interviewed in their homes to 
ascertain demographic characteristics and self-reported vaccination against hepatitis A. 
More information on survey design, including Institutional Review Board approval for data 
collection and analysis, and informed consent procedure, is available from survey 
documentation at http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm
2.2. Laboratory testing
Serum specimens from participants aged ≥2 years were tested for total anti-HAV using a 
competitive immunoassay technique (HAV T–Anti-HAV Total, VITROS 
Immunodiagnostic System (Ortho-Clinical Diagnostics, Inc., Rochester, NY)). Presence of 
total anti-HAV indicates immunity against HAV infection acquired from past infection or 
vaccination. Tests considered reactive initially were repeated in duplicate. Further details of 
laboratory testing are available from the survey documentation at http://www.cdc.gov/nchs/
nhanes/nhanes_questionnaires.htm
2.3. Definitions and measures
Self-reported HepA receipt was accessed from responses to the question “Hepatitis A 
vaccine is given as a two dose series to some children older than 2 years and also to some 
adults, especially people who travel outside the United States. It has only been available 
since 1995. Have you ever received hepatitis A vaccine?” Because seroconversion rates are 
high (~95%) after the first dose of HepA [15], we classified persons as “in agreement” with 
self-report when they reported receiving any doses of HepA and were anti-HAV positive, or 
if they reported no doses and were anti-HAV negative. We classified persons as “not in 
agreement” when they reported receiving any doses of HepA and were anti-HAV negative, 
or if they reported no doses and were anti-HAV positive.
Race and ethnicity were obtained by self-report from all NHANES participants. Prior to 
release in NHANES public use data files, NCHS combines responses on ethnicity and race 
into a limited number of categories. For 2007–2010 the categories were Mexican-American, 
Other Hispanic, Non-Hispanic Black, Non-Hispanic White and Other Race – Including 
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Multi-Racial; for 2011–2012, 6 categories were used: those used for 2007–2010 plus Asian. 
In our analysis we used the 2007–2010 categories, with Asian recoded into Other Race for 
2011–2012. Due to insufficient sample sizes resulting from changes in oversampling over 
time, NCHS does not recommend producing estimates for any Hispanic subgroup other than 
Mexican-American or for the Other Race subgroup. Therefore, estimates for these groups 
are not provided although participants belonging to these groups were included in the 
analyses.
2.4. Statistical analysis
We used SUDAAN (version 10.0), a statistical package designed to analyze complex survey 
data, for analysis [16]. Estimates were weighted to represent the total civilian, non-
institutionalized U.S. population and to account for oversampling and non-response to the 
household interview and physical examination. Weights were further adjusted to account for 
analyzing multiple years of data. We included only those aged ≥20 years in our analyses. A 
p-value <.05 was considered significant.
We estimated demographic (age at interview, sex, race/ethnicity, poverty index, birth place 
and education) and other (health insurance coverage) characteristics for groups obtained by 
combining vaccination report and anti-HAV test results: Group 1 reported receiving any 
doses of HepA and were anti-HAV negative, Group 2 reported any doses and were anti-
HAV positive, Group 3 reported no doses and were anti-HAV negative, and Group 4 
reported no doses and were anti-HAV positive. For each group and characteristic we 
calculated three measures of agreement: percent with agreement between self-reported 
vaccination status and serological result, positive predictive value (PPV) and negative 
predictive value (NPV). We used predictive values to refer to the predictive value of self-
reported vaccination for serological status. Chi-square tests were used for statistical 
comparisons between subgroups as an overall test for difference across levels of a factor. To 
avoid multiple testing, pairwise differences across levels of a factor with >2 levels and 
differences in PPV and NPV were determined by observing whether each estimate was 
contained within the 95% confidence interval of the other.
We conducted two separate logistic regression analyses to assess factors associated with 
agreement using the aforementioned characteristics. One analysis included only those who 
reported receiving any doses of HepA (Groups 1 and 2) and the other including only those 
who reported receiving no doses (Groups 3 and 4). In each regression analysis, crude 
prevalence ratios were obtained using a separate logistic regression model for each of the 
independent variables. Variables that were statistically significant in simple logistic models 
were included in initial multivariate modeling. Variables not found to be significant in 
simple logistic models or at earlier stages of model building were added to the final 
multivariate model one at a time to test for confounding and significance. Final models 
included all variables found to be significant and any potential confounders (e.g., sex).
3. Results
Of 24,731 persons aged ≥20 years sampled in the NHANES 2007–2012, 17,713 (71.6%) 
were interviewed and 17,085 (96.4% of those interviewed) were examined. Serum samples 
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were available for anti-HAV testing for 15,747 (92.2% of those examined). Of the 17,713 
interviewed, 15,375 (86.8%) provided a valid response to the hepatitis A vaccination 
question, 12 (0.07%) responded “don’t know” and 2326 (13.13%) refused to answer. 
Because not every participant with an anti-HAV result responded to the vaccination 
question, the sample size for our analysis was 13,651 (79.9% of those examined had data for 
both).
Overall, an estimated 26.2% (95% CI 24.7–27.8) self-reported HepA receipt and 34.8% 
(32.7–37.1) were anti-HAV positive. By group, 13.9% (13.0–14.9, n = 1622) reported 
receiving any HepA doses but were anti-HAV negative (Group 1), 12.3% (11.2–13.5, n = 
1901) reported any doses and were antibody positive (Group 2), 51.3% (49.0–53.5, n = 
5606) reported no doses and were antibody negative (Group 3) and 22.5% (20.9–24.3, n = 
4522) reported no doses but were anti-HAV positive (Group 4).
Except for sex, demographic and other characteristics varied significantly across the 4 
groups (Table 1). Group 1 (those who reported vaccination but were anti-HAV negative) 
were the youngest. Group 3 (those who reported no vaccination and were anti-HAV 
negative) were most likely to be non-Hispanic White and least likely to be Mexican-
American, and most likely to have income at or above poverty level or to have health 
insurance coverage. Group 4 (those who reported no vaccination but were anti-HAV 
positive) were the oldest, least likely to be non-Hispanic White, and most likely to have 
education less than high school. Regardless of vaccination history, Groups 2 and 4 (those 
who were anti-HAV positive) were most likely to be foreign-born, and Groups 1 and 3 
(those who were anti-HAV negative) were most likely to be US-born.
Overall agreement between self-reported hepatitis A vaccination and serological results was 
63.6% (61.9–65.2) (Table 2). Overall PPV of self-report was 47.0% (44.2–49.8) and NPV 
was 69.4% (67.0–71.8). NPV was highest for those aged <60 years at interview, non-
Hispanic Whites, and those with income at or above poverty level, education above high 
school, US birth, and health insurance coverage. PPV was highest for those aged ≥60 years, 
Mexican-Americans and those who were foreign born. Sex was not predictive of agreement.
Simple logistic regression analysis involving those who reported receiving HepA (Groups 1 
and 2) found significant positive associations between agreement with serologic results and 
Mexican-American race/ethnicity and foreign birth and significant negative associations 
between agreement and age <60 years at interview and education greater than or equal to 
high school; sex, poverty level and health insurance coverage were not significantly 
associated with agreement in simple logistic models (Table 3) Simple logistic regression 
analysis involving those who reported no doses (Groups 3 and 4) found significant positive 
associations between agreement with serologic results and age <60 years at interview and 
education greater than or equal to high school and significant negative associations between 
agreement and Mexican-American and Black non-Hispanic race/ethnicity, income below 
poverty level, non-US birth, and no health insurance coverage; only sex was not 
significantly associated with agreement in simple logistic models (Table 4). In the final 
multivariate logistic models, all factors significant in the simple logistic analyses except 
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health insurance coverage retained their significant associations with agreement with 
serologic results (Tables 3 and 4).
4. Discussion
NHANES data provide a unique opportunity to assess agreement between self-reported 
HepA receipt and serological evidence of anti-HAV protection in a nationally representative 
sample of the U.S. adult population. We found overall agreement was 63.6%, similar to 
[10,18] or a little lower [17,19] than findings for other vaccines. PPVs >70% were found 
among Mexican American and foreign born adults, and NPVs >76% were found among 
young, US-born, and non-Hispanic White adults. Of concern, PPVs of self-reported HepA 
receipt were <40% among young, US-born, and non-Hispanic White adults, suggesting a 
large proportion of adults in these groups might believe they are protected against HAV 
infection when they are not.
Lack of easily accessible adult vaccination records and lack of health-care provider and 
patient knowledge about the need for vaccination have been identified as barriers to adult 
vaccination [20]. Adult self-reported hepatitis A vaccination coverage among persons 
recommended for vaccination was estimated at <20% in the 2012 National Health Interview 
Survey [21]. When vaccination records are not available, determining which patients will 
benefit from hepatitis A vaccination presents a challenge for providers assessing adults who 
might be at risk for HAV infection or for severe HAV disease, e.g., injecting and non-
injecting drug users, men who have sex with men, persons working with HAV-infected 
primates or who have chronic liver disease [4]. Lack of records also is a barrier to making 
rapid vaccination decisions needed for impending international travel and for known HAV 
exposure [5,13]. A false impression of protection might leave the patient unprotected; 
unnecessary vaccination adds cost and inconvenience. Current recommendations for 
obtaining pre-vaccination serologic testing to determine HAV protection suggest 
considering the expected prevalence of anti-HAV, the cost of vaccination compared with the 
cost of serologic testing and an additional visit, and the likelihood that testing will not 
interfere with needed vaccination [4,22]. These recommendations were based on the results 
of NHANES surveys conducted in 1988–1994, which found that the prevalence of anti-
HAV was >33% among adults aged >40 years [4,23]. In contrast, NHANES data from 2009 
to 2010 found the prevalence of anti-HAV among U.S.-born adults did not reach >33% until 
persons were aged ≥60 years, highlighting the increasing proportion of U.S. adults who are 
hepatitis A susceptible. (Public Health Grand Rounds, April 2013. Available at: http://
www.cdc.gov/cdcgrandrounds/archives/2013/april2013.htm).
Most current national systems for assessing adult vaccination coverage rely on self-report of 
vaccination [18,24]. Reliable data assessing vaccine coverage among adults is important for 
public health to assess programmatic success and to identify gaps in coverage. In 
conjunction with surveillance for determining disease incidence, vaccine coverage data 
provide information for planning targeted vaccination among persons who will benefit 
[24,25]. Greater focus on adult immunization has stimulated efforts to include adult 
vaccination as a standard of care in electronic medical records and in Immunization 
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Information Systems (IIS) registries for adults [20,26,27]. Registries will likely improve 
assessment of adult vaccination status.
A major advantage of NHANES data for assessing the validity of self-reported HepA receipt 
is its relatively large sample size, which allows for assessing groups of adults with relatively 
low vaccination coverage. NHANES data also reflect HAV protection from infection as well 
as from vaccination, which may be more relevant in the context of changing disease and 
susceptibility patterns in the population. NHANES data have previously been used to assess 
the validity of self-reported hepatitis B vaccination. A limitation of these analyses was 
waning of hepatitis B vaccine-induced antibody to levels no-longer defined as protective 
[28]. In contrast, after hepatitis A vaccination, anti-HAV has persisted in the majority of 
responders since vaccines were approved for use in 1995–1996; mathematical modeling 
suggests persistence of vaccine-induced anti-HAV might be ≥25 years in as many as 95% of 
the population [29–32].
Our findings are generally in accord with those of others [10,12,33]. Rolnick et al. examined 
self-reported HepA receipt with confirmation in electronic medical records or on vaccination 
cards [10]. In their study non-Hispanic Whites comprised 85% of subjects, none were 
Hispanic, and 79% had some college or higher education. HepA coverage in electronic 
records was 15.7% in the source population; in contrast, anti-HAV was found in 34.8% of 
subjects in our analysis of NHANES data. Self-reported HepA coverage in Rolnick et al. 
was 23.3% among interviewed subjects, similar to selfreported coverage in NHANES 
(26.2%). The NPV of self-reported vaccination in Rolnick et al. was 94.0%, substantially 
higher than the 69.4% in NHANES. Overall, PPVs were similar in Rolnick et al. and 
NHANES (42.1% and 47.0%, respectively). Among older adults, Rolnick et al. reported 
lower PPV than found in NHANES (39.9% for ages ≥65, and 64.7% for ages ≥60 years, 
respectively). Mongillo et al. examined NPV and PPV of agreement between self-reported 
HepA receipt and presence of anti-HAV among Italian college students aged <30 years [12]. 
NPV (96.1%) and PPV (52.7%) of self-reported vaccination were slightly higher than found 
in NHANES among persons ages 20–29 years (76.9% and 37.9%, respectively), but the 
pattern was similar. Discrepancies between our results and those of Rolnick et al. and 
Mongillo et al., likely reflect the outcomes evaluated (confirmed vaccination or anti-HAV), 
and the characteristics of the populations surveyed [10,12].
Our results have unavoidable limitations. The classification for agreement between self-
reported HepA receipt and serological status had potential for misclassification of persons 
who were previously HAV infected but reported no vaccination, or the small proportion of 
vaccinated persons who do not respond with anti- HAV. However, our objective was to 
determine whether self-report of vaccination reflected protection measured as anti-HAV, 
regardless of the source of protection (vaccination or infection). We assumed the presence of 
anti-HAV indicated protection against HAV disease primarily through vaccination, but 
misclassification could have occurred if anti-HAV was acquired through past infection. 
NHANES does not ask for hepatitis A disease history and laboratory assays do not 
distinguish between anti-HAV acquired through infection and anti-HAV induced by 
vaccination. We assumed that adults who received either one or two doses of the 
recommended two-dose HepA series had measurable anti- HAV. Although seroconversion 
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rates after the first dose are high (~95%), some vaccinated adults would not have 
seroconverted, and these adults would have been misclassified as lacking agreement [12,34]. 
The NHANES question about hepatitis A vaccination indicates the vaccine is given to 
children ages ≥2 years; this might have caused confusion by some participants since HepA 
has been recommended at age 12–23 months since 2006 and also for some adults [4]. 
NHANES data are representative of the civilian, non-institutionalized U.S. population but 
do not include persons who are homeless, in the military, or living in group quarters (e.g., 
college students). Thus, the results might not apply to the entire U.S. population. Lastly, 
measures of agreement between self-report and anti-HAV are at population level and do not 
directly address results for an individual whose hepatitis A protection is being evaluated.
In conclusion, findings from NHANES 2007–2012 document the limitations of self-reported 
HepA receipt. They illustrate that providers caring for adults (especially non-Hispanic 
Whites) in the United States should be aware that self-reported HepA receipt has a relatively 
low PPV for hepatitis A protection; this is particularly relevant given that a substantial 
proportion of the U.S. adult population is susceptible to HAV infection. Findings from this 
analysis might alert providers to avoid missed opportunities to vaccinate susceptible 
individuals and to avoid vaccinating persons who are already protected. These findings also 
provide information to public health vaccination programs and providers regarding the 
characteristics of persons whose self-reported hepatitis A vaccination status most reliably 
predicts HAV protection, and the need for additional education about the risks of HAV 
disease and the benefits of hepatitis A vaccination.
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Table 3
Crude (CPR) and adjusted prevalence ratios (APR) for factors associated with agreement between self-report 
of hepatitis A vaccination and HAV serological testing (Groups 1 and 2) medical examination participants: 
NHANES 2007–2012 aged ≥20 years.
Factor Simple logistic model Final multivariate logistic model
CPR (95% CI) p-value* APR (95% CI) p-value†
Age at interview (years)
  20–29 0.59 (0.51–0.67) <.001 0.56 (0.49–0.64) <.001
  30–39 0.71 (0.62–0.82) <.001 0.65 (0.57–0.74) <.001
  40–49 0.70 (0.61–0.80) <.001 0.66 (0.58–0.76) <.001
  50–59 0.80 (0.72–0.89) <.001 0.78 (0.70–0.87) <.001
  60+ (ref) – – – –
Sex
  Male 1.07 (0.98–1.15) .113 1.05 (0.97–1.13) .242
  Female (ref) – – – –
Race/ethnicity
  Mexican-American 1.80 (1.60–2.02) <.001 1.58 (1.40–1.78) <.001
  White non-Hispanic (ref) – – – –
  Black non-Hispanic 1.07 (0.94–1.22) .318 1.13 (1.02–1.25) .019
Poverty index
  Below poverty 1.01 (0.89–1.16) .838 NS –
  At or above poverty (ref) – –
Education
  <High school (ref) – – – –
  High school/GED 0.69 (0.59–0.79) <.001 0.84 (0.73–0.96) .013
  >High school 0.82 (0.73–0.91) .001 1.03 (0.92–1.15) .574
Place of birth
  United States (ref) – – – –
  Elsewhere 1.94 (1.76–2.14) <.001 1.72 (1.54–1.92) <.001
Health insurance
  Any (ref) – –
  None 0.99 (0.86–1.13) .844 NS –
NS = variable not significant in simple logistic model or when added to final multivariate logistic model and therefore not included in the final 
multivariate model. Final model includes all variables found to be significant and potential confounds such as sex, even if not significant.
*
p-value for significance of beta coefficients from simple logistic models.
†
p-value for significance of beta coefficients from the final multivariate logistic model.
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Table 4
Crude (CPR) and adjusted prevalence ratios (APR) for factors associated with agreement between self-report 
of no hepatitis A vaccination and HAV serological testing (Groups 3 and 4) medical examination participants: 
NHANES 2007–2012 aged ≥20 years.
Factor Simple logistic model Final multivariate logistic model
CPR (95% CI) p-value* APR (95% CI) p-value†
Age at interview (years)
  20–29 1.36 (1.25–1.48) <.001 1.51 (1.41–1.61) <.001
  30–39 1.32 (1.23–1.42) <.001 1.49 (1.40–1.58) <.001
  40–49 1.36 (1.28–1.45) <.001 1.47 (1.39–1.55) <.001
  50–59 1.27 (1.20–1.35) <.001 1.32 (1.25–1.39) <.001
  60+ (ref) – – – –
Sex
  Male 1.01 (0.98–1.04) .563 1.02 (0.99–1.05) .154
  Female (ref) – – – –
Race/ethnicity
  Mexican-American 0.27 (0.23–0.32) <.001 0.49 (0.43–0.57) <.001
  White non-Hispanic (ref) – – – –
  Black non-Hispanic 0.78 (0.73–0.83) <.001 0.79 (0.75–0.85) <.001
Poverty index
  Below poverty 0.76 (0.70–0.83) <.001 0.95 (0.92–0.98) .001
  At or above poverty (ref) – – – –
Education
  <High school (ref) – – –
  High school/GED 1.63 (1.50–1.76) <.001 1.16 (1.11–1.21) <.001
  >High school 1.79 (1.63–1.97) <.001 1.24 (1.19–1.30) <.001
Place of birth
  United States (ref) – – – –
  Elsewhere 0.25 (0.22–0.30) <.001 0.47 (0.42–0.53) <.001
Health insurance
  Any (ref) – –
  None 0.83 (0.76–0.90) <.001 NS –
NS = variable not significant in earlier stages of multivariate modeling and not included in the final multivariate logistic model. Final model 
includes all variables found to be significant and potential confounds such as sex, even if not significant.
*
p-value for significance of beta coefficients from simple logistic models.
†
p-value for significance of beta coefficients from the final multivariate logistic model.
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